Navigating the Changing Landscape in HER2-Positive Breast Cancer
March 9th 2020The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD
Read More
CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers
October 31st 2017A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.
Read More
Biomarker Basics: A Look at MSI's Growing Role
August 2nd 2017The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.
Read More